oben
spacer
Welcome to Slovenský hematolologický portál
Janssen Cilag
   Home   Moje Konto   Témy   Fórum   Downloads   

  Menu
· Úvodná stránka
· Stories Archive
· Forums
· Download
· Encyclopedie
· Search
· Your Account
· Statistics
· Members List
· Topics
· Submit News
· Web Links

  Vedenie odboru
Prezident SHaTS
Hlavný odborník
· pre hematológiu
· pre transfuziológiu
· pre det.hematológiu
Krajskí odborníci
· pre hematologiu
· pre transfuzologiu

  Gaucherova choroba

  Gaucherova choroba

  AMGEN

  SHaTS

  

  Edukacné centrum

  NTS SR

  NR DKD

  SMS

  SSHT

  Lymfomova skupina

  trombocytopenie

  Fakultné pracoviská
· KHaT FNsP Bratislava
· KHaT FNsP Martin
· KHaOH FN LP Košice
· Odbor H a T

  Pracoviská HaT
· Bratislavský kraj
· Trnavský kraj
·
Nitrianský kraj
· Trenčiansky kraj
· Banskobystrický kraj
·
Žilinský kraj
· Prešovský kraj
· Košický kraj

  
· Hematológia
· Transfuziológia
· Laboratórna medicína
· Cytogenetika
· Hematoonkológia
· Transplantácia
· Hemostáza a tromb.
· Imunohematológia
· Klinické registre
· Knižnice
· Asociácie, spoločnosti
· MZd

  Kto je Online
Momentálne je online 413 hostí a 0 členov.

Ste anonymný užívateľ. Zaregistrovať sa môžete tu

  
Prevzaté: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Pur
Posted on 30.10.2009 17:31
Topic: Trombocytopenia

Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura

Donald M. Arnold, MD, MSc; Francesco Dentali, MD; Mark A. Crowther, MD, MSc; Ralph M. Meyer, MD; Richard J. Cook, PhD; Christopher Sigouin, MSc; Graeme A. Fraser, MD; Wendy Lim, MD, MSc; and John G. Kelton, MD
Corresponding Author: Donald M. Arnold, MD, McMaster University Health Sciences Center, Room 3N-43, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada; e-mail, arnold@mcmaster.ca.

Ann Intern Med. 2007;146:25-33. www.annals.org



Background: Rituximab, a monoclonal anti-CD20 antibody, is increasingly used to treat idiopathic thrombocytopenic purpura (ITP).
Purpose: To systematically review the literature on the efficacy and safety of rituximab for the treatment of adults with ITP.
Study Selection: Descriptive and comparative studies in any language that met predefined inclusion criteria were eligible. Efficacy analysis was restricted to studies enrolling 5 or more patients.
Data Extraction: Platelet count response, toxicities, dose, previous treatments, baseline platelet count, duration of ITP, study design, and sources of funding were extracted in duplicate.
Data Synthesis: We identified 19 eligible reports on efficacy (313 patients) and 29 on safety (306 patients). Weighted means for complete response (platelet count >150x10/9 cells/L) and overall response (platelet count >50x10/9 cells/L) with rituximab were 43.6% (95% CI, 29.5% to 57.7%) and 62.5% (CI, 52.6% to 72.5%), respectively. Responses lasted from 2 to 48 months. Nearly all patients had received corticosteroids, and 53.8% had undergone splenectomy. Nine patients (2.9%) died.
Limitations: There were no controlled studies, and no studies met all criteria for study quality. Reported deaths could not necessarily be attributed to rituximab. Overall, the number of rituximab-treated patients with ITP reported in the literature is small.
Conclusions: Rituximab resulted in an overall platelet count response in 62.5% of adults with ITP. However, this finding derives from uncontrolled studies that also reported significant toxicities, including death in 2.9% of cases. These data suggest that providers should avoid indiscriminate use of rituximab and that randomized, controlled trials of rituximab for ITP are urgently needed.

pozri článok

 
  Prihlásenie
Užívateľské meno

Heslo

Ešte nemáte konto? Môžete si ho vytvoriť. Registrovaný užívateľ má niektoré výhody, napr. manažér tém, nastavenie komentárov a posielanie komentárov s vlastným menom.

  Príbuzné odkazy
· Viac o Trombocytopenia
· Iné články od: ornst


Najčítanejšie články Trombocytopenia:
Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP)


  Hodnotenie článku
Priemerné skóre: 1
hlasov: 5


Obetujte prosím chvíľku hodnoteniu tohto článku:

Vynikajúci
Veľmi dobrý
Dobrý
Priemerný
Zlý


  Možnosti

 Stránka vhodná na tlač Stránka vhodná na tlač


Komentáre k tomuto článku nie sú dostupné.
fuss

hematology | car tuning | Identifikační náramky | Identifikačné Náramky


© 2005 created by maxiweb.sk

Generovanie stránky 0.71 sekund